Description: PolyNovo Limited is a medical device company. The Company designs, develops and manufactures solutions for standalone and combination devices using its NovoSorb biodegradable polymer technology. The Company focuses on medical devices that are used in the treatment of burns, surgical wounds and negative pressure wound therapy (NPWT). It is involved in the development of NovoPore for use as a dressing in NPWT that involves a wound-contacting foam dressing, a sealing membrane, a suction pump, and a drainage tube from the dressing to a canister, and Biodegradable Temporising Matrix (BTM), a wound dressing focused on treatment of full-thickness wounds and burns where the dermal structure has been lost to trauma, or damaged requiring surgical removal, and requires a split-thickness skin graft for final closure. In addition, the Company is engaged in the development of breast sling prototypes for non-clinical and clinical trials, as well as new products for hernia and breast reconstructions.
Home Page: polynovo.com
PNV Technical Analysis
Putnam Investment Funds
,
Phone:
61 3 8681 4050
Officers
Name | Title |
---|---|
Mr. Jan-Marcel Gielen C.A. | CFO & Company Sec. |
Dr. David McQuillan Ph.D. | Chief Technical & Scientific Officer |
Mr. Swami Raote BPHARM, M.B.A. | CEO & Director |
Mr. Ahmed Hassan | Director of Operations |
Ms. Teena Chadha | APAC Marketing & Distributor Mang. |
Ms. Monica Benyk | HR Mang. |
Dr. Tim Moore | Principal Scientist |
Mr. Edward Graubart | Sr. VP of Sales & Marketing (Americas) |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 30.7692 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 76.4859 |
Price-to-Sales TTM: | 33.6394 |
IPO Date: | |
Fiscal Year End: | June |
Full Time Employees: | 152 |